Proliferation Indices As Molecular Pharmacodynamic Endpoints in Evaluation of Anticancer Drug Effect in Human Solid Tumors

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 1998 Oct 30

PMID 9794496

Authors

J R Weaver

Y Gan

J L Au

Affiliations

Soon will be listed here.

Abstract

Purpose: The present study compared proliferative indices, i.e. incorporation of DNA precursor (i.e. thymidine or TdR, and bromodeoxyuridine or BrdU) and expression of proliferating cell nuclear antigen (PCNA), as molecular pharmacodynamic endpoints in evaluation of anticancer drug effect in human solid tumors.

Methods: Tumor specimens obtained from patients were grown as histocultures. After treatment with doxorubicin, mitomycin C, and/or paclitaxel, cells labeled by [3H]TdR were identified using autoradiography, and cells labeled by BrdU and PCNA were identified using immunohistochemical techniques. Drug effect was measured as reduction of DNA precursor-labeled cells or PCNA-expressing cells.

Results: The results indicate that (a) the two DNA precursors, TdR and BrdU, labeled the same cells and resulted in identical pharmacodynamics, (b) the pharmacodynamics established using inhibition of DNA precursor incorporation were qualitatively and quantitatively different from the pharmacodynamics established using inhibition of PCNA expression, (c) the inhibition of PCNA expression was erratic in some tumors, and (d) the differences in pharmacodynamics established using the two end points are drug-specific, with greater differences for paclitaxel than for mitomycin C.

Conclusions: The erratic results measured by the PCNA labeling method suggest that this method may be less reliable than the conventional DNA precursor labeling method. The finding of identical pharmacodynamics of doxorubicin and paclitaxel established using BrdU and [3H]TdR indicates that the two precursors are interchangeable. Because the methodology for detecting BrdU incorporation requires less time and does not require the use of radioactivity, we conclude that inhibition of BrdU incorporation represents a useful endpoint for evaluating the antiproliferative activity of anticancer drugs in human solid tumors.

References

Gan Y, Wientjes M, Schuller D, Au J . Pharmacodynamics of taxol in human head and neck tumors. Cancer Res. 1996; 56(9):2086-93. View

Yonemura Y, Kamata T, Ohoyama S, Matumoto H, Kimura H, Kosaka T . Relation of proliferative activity to survival in patients with advanced gastric cancer. Anal Cell Pathol. 1991; 3(2):103-10. View

Weidner N, Moore 2nd D, Ljung B, Waldman F, Goodson 3rd W, Mayall B . Correlation of bromodeoxyuridine (BRDU) labeling of breast carcinoma cells with mitotic figure content and tumor grade. Am J Surg Pathol. 1993; 17(10):987-94. DOI: 10.1097/00000478-199310000-00003. View

Soames A, Lavender D, Foster J, Williams S, Wheeldon E . Image analysis of bromodeoxyuridine (BrdU) staining for measurement of S-phase in rat and mouse liver. J Histochem Cytochem. 1994; 42(7):939-44. DOI: 10.1177/42.7.8014477. View

Schmittgen T, Weaver J, Badalament R, Wientjes M, Klein E, Young D . Correlation of human bladder tumor histoculture proliferation and sensitivity to mitomycin C with tumor pathobiology. J Urol. 1994; 152(5 Pt 1):1632-6. DOI: 10.1016/s0022-5347(17)32493-x. View

Sebo T, Roche P, Witzig T, Kurtin P . Proliferative activity in non-Hodgkin's lymphomas. A comparison of the bromodeoxyuridine labeling index with PCNA immunostaining and quantitative image analysis. Am J Clin Pathol. 1993; 99(6):668-72. DOI: 10.1093/ajcp/99.6.668. View

Furukawa T, Kubota T, Hoffman R . Clinical applications of the histoculture drug response assay. Clin Cancer Res. 1995; 1(3):305-11. View

Jain S, FILIPE M, Hall P, Waseem N, Lane D, Levison D . Prognostic value of proliferating cell nuclear antigen in gastric carcinoma. J Clin Pathol. 1991; 44(8):655-9. PMC: 496758. DOI: 10.1136/jcp.44.8.655. View

Hall P, Woods A . Immunohistochemical markers of cellular proliferation: achievements, problems and prospects. Cell Tissue Kinet. 1990; 23(6):505-22. DOI: 10.1111/j.1365-2184.1990.tb01343.x. View

10.

Bravo R, Frank R, Blundell P . Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta. Nature. 1987; 326(6112):515-7. DOI: 10.1038/326515a0. View

11.

Galand P, Degraef C . Cyclin/PCNA immunostaining as an alternative to tritiated thymidine pulse labelling for marking S phase cells in paraffin sections from animal and human tissues. Cell Tissue Kinet. 1989; 22(5):383-92. DOI: 10.1111/j.1365-2184.1989.tb00223.x. View

12.

Bravo R . Existence of two populations of cyclin/proliferating cell nuclear antigen during the cell cycle: association with DNA replication sites. J Cell Biol. 1987; 105(4):1549-54. PMC: 2114668. DOI: 10.1083/jcb.105.4.1549. View

13.

Eldridge S, Tilbury L, Goldsworthy T, Butterworth B . Measurement of chemically induced cell proliferation in rodent liver and kidney: a comparison of 5-bromo-2'-deoxyuridine and [3H]thymidine administered by injection or osmotic pump. Carcinogenesis. 1990; 11(12):2245-51. DOI: 10.1093/carcin/11.12.2245. View

14.

Coltrera M, Gown A . PCNA/cyclin expression and BrdU uptake define different subpopulations in different cell lines. J Histochem Cytochem. 1991; 39(1):23-30. DOI: 10.1177/39.1.1670579. View

15.

Kubota T, Sasano N, Abe O, NAKAO I, Kawamura E, Saito T . Potential of the histoculture drug-response assay to contribute to cancer patient survival. Clin Cancer Res. 1995; 1(12):1537-43. View

16.

Giordano M, Danova M, Mazzini G, Gobbi P, Riccardi A . Cell kinetics with in vivo bromodeoxyuridine assay, proliferating cell nuclear antigen expression, and flow cytometric analysis. Prognostic significance in acute nonlymphoblastic leukemia. Cancer. 1993; 71(9):2739-45. DOI: 10.1002/1097-0142(19930501)71:9<2739::aid-cncr2820710909>3.0.co;2-b. View

17.

Thornton J, Wells M, Hume W . Flash labelling of S-phase cells in short-term organ culture of normal and pathological human endometrium using bromodeoxyuridine and tritiated thymidine. J Pathol. 1988; 154(4):321-8. DOI: 10.1002/path.1711540407. View

18.

Robbins K, Connors K, Storniolo A, Hanchett C, Hoffman R . Sponge-gel-supported histoculture drug-response assay for head and neck cancer. Correlations with clinical response to cisplatin. Arch Otolaryngol Head Neck Surg. 1994; 120(3):288-92. DOI: 10.1001/archotol.1994.01880270036007. View

19.

Au J, Wientjes M, Rosol T, Goebel E, Schuller D . Histocultures of patient head and neck tumors for pharmacodynamics studies. Pharm Res. 1993; 10(10):1493-9. DOI: 10.1023/a:1018935628085. View

20.

Pich A, Margaria E, Chiusa L . Proliferative activity is a significant prognostic factor in male breast carcinoma. Am J Pathol. 1994; 145(2):481-9. PMC: 1887387. View